Filing Flows › Castle Biosciences (CSTL) › Q2 2026
Castle Biosciences (CSTL) Q2 2026 earnings results (second quarter 2026)
10-Q filed Jul 30, 2026
Castle Biosciences (CSTL) reported revenue of $104M for the second quarter 2026 (Q2 2026), +20% from a year earlier and +24% from the quarter before. Operating margin was -3.0%, net loss $2.1M (2.0% of revenue).
Castle Biosciences, Q2 2026: revenue $104M (+20% year over year), operating margin -3.0%, net loss $2.1M, operating cash flow $15.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $104M | +24% | +20% |
| Operating profit | −$3.1M | — | — |
| Net earnings | −$2.1M | — | -146% |
| Operating cash flow | $15.2M | — | -27% |
| Free cash flow | $6.6M | — | -43% |
What changed
Revenue was $103.5M in Q2 2026, up 20% year over year and up 24% from the previous quarter. Non-Dermatologic was the largest line at 53% of revenue. Non-Dermatologic added $25.0M year over year (up 83%), 144% of the total change. Dermatologic declined 13%.
Operating costs exceeded revenue by $3.1M, an operating margin of -3.0%. Total costs grew 18% against revenue growth of 20%. The fastest-growing cost line was Cost of revenue (+34%). The quarter ended with a net loss of $2.1M, narrower than the previous quarter's $14.5M loss. Non-operating items added $1.4M, -82% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $15.2M (down 27% year over year). Non-cash charges added back $4.1M of depreciation and amortization and $11.6M of share-based compensation. Working capital and other items added $1.6M. Capital expenditures of $8.7M left free cash flow of $6.6M.
Questions
What was Castle Biosciences' revenue in the second quarter 2026?
Castle Biosciences (CSTL) reported revenue of $104M for the second quarter 2026 (Q2 2026), +20% from a year earlier and +24% from the quarter before.
Was Castle Biosciences profitable in the second quarter 2026?
Operating loss was $3.1M (-3.0% of revenue) and net loss $2.1M.
Source: Castle Biosciences 10-Q on SEC EDGAR.